Immatics US, Inc.
Overview
Immatics is focused on precision targeting of PRAME, a target expressed in more than 50 cancers, and is evaluating its targeted PRAME cell therapies and bispecific product candidates in clinical trials.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to Immatics US, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.